Lutathera - Lutetium LU 177 Dotatate – Radiopharmaceuticals - INTENT TO SOLE SOURCE
Closed Special Notice Posted
- Solicitation number
- 36C25225Q0635
- Agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Hines, Illinois 60141, United States
- Points of contact
-
- Tiffany Pevey tiffany.pevey@ca.gov (414) 384-3224
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Network Contracting Office 12 has issued a Special Notice announcing its intent to award a sole source contract for Lutathera - Lutetium LU 177 Dotatate, a radiopharmaceutical product. The contract, valued at $297,477.53, is intended for Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, covering the procurement of 7 doses of the NDC number 69488-0003-01 product. This firm fixed-price contract falls under the pharmaceutical preparation manufacturing sector and is classified as a drugs and biologicals procurement. The VA is pursuing this acquisition under 41 U.S.C. 3304(a)(1) as a single-source award, citing Novartis as the only identified responsible source capable of meeting agency requirements. The performance period is anticipated to span 8 months to 1 year.
The primary purpose of this Special Notice is to provide transparency regarding the VA's intent to proceed with a sole source procurement while allowing other potential contractors an opportunity to demonstrate their capabilities. Interested parties must submit capability documentation by July 30, 2025, at 3:00 PM CST to be considered as alternative sources for this requirement. All responses must be submitted via email to Contracting Officer Tiffany Pevey, and potential contractors must maintain active registration in the System for Award Management (SAM) to be eligible for consideration. The anticipated contract award date is August 1, 2025, providing a tight timeline for both the response period and contract execution. This procurement represents a specialized radiopharmaceutical acquisition that requires specific manufacturing capabilities and regulatory compliance for veterans' healthcare needs.
Notice text
The Department of Veterans Affairs, Network Contracting Office 12, hereby provides notice of its Intent to award a Sole Source, firm fixed price contract NDC number 69488-0003-01 Lutathera - Lutetium LU 177 Dotatate to a large business Novartis Pharmaceuticals Corporation, One Health Plaza East Hanover, NJ 07936-1080.
Files
| File | Type | Posted |
|---|---|---|
| S02 - 36C25225Q0635 - Intent to Sole Source.docx | DOCX document |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--INTENT TO SOLE SOURCE Radiopharm - Lutathera & Pluvicto - Lebanon VAMC | Veterans Integrated Service Network 4 | No set-aside | |
| 6505--VA Long Beach Pylarify | Veterans Integrated Service Network 22 | No set-aside | |
| 6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052 | Veterans Integrated Service Network 10 | No set-aside | |
| 6505--FY27 Lenalidomide BPA | Veterans Integrated Service Network 22 | No set-aside | |
| 7A20--Software, Materialise MIMICS License Renewal, IND | Veterans Integrated Service Network 10 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity